NTRA vs. SNY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at NTRA and SNY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
NTRA is a standard domestic listing, while SNY trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | NTRA | SNY |
|---|---|---|
| Company Name | Natera, Inc. | Sanofi |
| Country | United States | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 28.52 billion USD | 123.41 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | July 1, 2015 | July 1, 2002 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of NTRA and SNY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | NTRA | SNY |
|---|---|---|
| 5-Day Price Return | 5.18% | 0.58% |
| 13-Week Price Return | 31.58% | 6.32% |
| 26-Week Price Return | 29.06% | -3.23% |
| 52-Week Price Return | 58.47% | -8.04% |
| Month-to-Date Return | 3.87% | -0.90% |
| Year-to-Date Return | 30.53% | -7.39% |
| 10-Day Avg. Volume | 1.56M | 1.47M |
| 3-Month Avg. Volume | 1.28M | 1.87M |
| 3-Month Volatility | 32.82% | 28.60% |
| Beta | 1.65 | 1.07 |
Profitability
Return on Equity (TTM)
NTRA
-25.07%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
NTRA has a negative Return on Equity of -25.07%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
SNY
18.76%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
SNY’s Return on Equity of 18.76% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
NTRA
-14.61%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
NTRA has a negative Net Profit Margin of -14.61%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
SNY
20.66%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 20.66% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
NTRA
-16.62%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
NTRA has a negative Operating Profit Margin of -16.62%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
SNY
20.74%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
SNY’s Operating Profit Margin of 20.74% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | NTRA | SNY |
|---|---|---|
| Return on Equity (TTM) | -25.07% | 18.76% |
| Return on Assets (TTM) | -17.74% | 10.65% |
| Net Profit Margin (TTM) | -14.61% | 20.66% |
| Operating Profit Margin (TTM) | -16.62% | 20.74% |
| Gross Profit Margin (TTM) | 63.66% | 72.29% |
Financial Strength
Current Ratio (MRQ)
NTRA
3.27
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
NTRA’s Current Ratio of 3.27 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
SNY
1.06
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
SNY’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
NTRA
0.06
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
NTRA’s Debt-to-Equity Ratio of 0.06 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
SNY
0.30
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
SNY’s Debt-to-Equity Ratio of 0.30 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
NTRA
-57.80
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
NTRA has a negative Interest Coverage Ratio of -57.80. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
SNY
22.06
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | NTRA | SNY |
|---|---|---|
| Current Ratio (MRQ) | 3.27 | 1.06 |
| Quick Ratio (MRQ) | 3.01 | 0.30 |
| Debt-to-Equity Ratio (MRQ) | 0.06 | 0.30 |
| Interest Coverage Ratio (TTM) | -57.80 | 22.06 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
NTRA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
SNY
4.62%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 4.62%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
NTRA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
SNY
52.56%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | NTRA | SNY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.62% |
| Dividend Payout Ratio (TTM) | 0.00% | 52.56% |
Valuation
Price-to-Earnings Ratio (TTM)
NTRA
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for NTRA is currently unavailable.
SNY
7.53
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 7.53 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
NTRA
13.51
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
NTRA’s P/S Ratio of 13.51 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SNY
1.56
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, SNY’s P/S Ratio of 1.56 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
NTRA
17.64
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
NTRA’s P/B Ratio of 17.64 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
SNY
1.32
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
SNY’s P/B Ratio of 1.32 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | NTRA | SNY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 7.53 |
| Price-to-Sales Ratio (TTM) | 13.51 | 1.56 |
| Price-to-Book Ratio (MRQ) | 17.64 | 1.32 |
| Price-to-Free Cash Flow Ratio (TTM) | 273.53 | 10.34 |